Oral immunotherapy (OIT) represents a promising therapeutic approach for severe food allergies. Two dosing strategies have emerged : conventional high-dose protocols and low-dose protocols.
Peanut oral immunotherapy
Standard maintenance doses
The FDA-approved product (Palforzia) uses a maintenance dose of 300 mg of peanut protein (equivalent to approximately 2 small peanuts), administered daily after a 6–12 month escalation phase. This dose achieves desensitization rates exceeding 80%.
Comparison of low vs high doses
Clinical trials have evaluated different maintenance doses :
- 300 mg : approved standard dose, offering a good balance between efficacy and safety
- 2000 mg : used in the IMPACT trial, showing high efficacy (71% desensitization at 5000 mg) but with more adverse events
- 4000 mg : high dose tested in the POISED study ; subsequent reduction to 300 mg showed a progressive loss of desensitization
The DEVIL trial demonstrated that in children aged 9 to 36 months, low doses (300 mg) provided comparable efficacy to high doses (3000 mg) with better tolerability.
Safety profile
Peanut OIT carries an approximately 14% risk of treatment-related anaphylaxis. Reactions may be exacerbated by physical exercise, fever, viral infections, and nonsteroidal anti-inflammatory drugs.
Milk oral immunotherapy
Fixed-dose vs escalation protocols
A recent randomized trial compared two strategies in children with severe milk allergy :
Low fixed-dose group
- Target dose : 3 mL (99 mg protein)
- Symptom frequency : 0.9% per dose in year 1, 0.8% in year 2
- Anaphylaxis : 0.01% in year 1
Escalation to medium-dose group
- Target dose : 25 mL (825 mg protein)
- Symptom frequency : 3.8% per dose in year 1, 2.0% in year 2
- Anaphylaxis : 0.06% in year 1
Comparable efficacy
Both protocols demonstrated similar efficacy in achieving short-term tolerance to 25 mL :
- At 1 year : 31% (fixed dose) vs 28% (escalation)
- At 2 years : 47% (fixed dose) vs 44% (escalation)
Other doses studied
Other trials have assessed various maintenance doses:
- 20 mL vs 100 mL : equivalent efficacy but improved safety with the lower dose (0.1% vs 0.5% severe symptoms)
- Very low-dose protocols : initial and maintenance doses tailored to severity, with gradual escalation targeting a tenfold increase over one year
Eosinophilic gastrointestinal reactions
Revised protocols with lower starting doses and slower escalation have reduced the severity of OIT-induced eosinophilic gastrointestinal reactions, with a significant reduction in severe presentations (45.5% vs 72.7%).
General dosing principles
Escalation strategy
OIT typically begins with doses measured in micrograms, followed by gradual increases up to the maintenance dose.
Maintenance of desensitization
Continuous daily ingestion of the maintenance dose is required to sustain desensitization, as discontinuation may lead to loss of protective benefit.
Sustained tolerance
Low-dose protocols have demonstrated sustained tolerance rates of :
- Milk : 33–50%
- Peanut : 33–74%
Conclusion
Recent data suggest that a low-dose OIT approach provides a superior safety profile while maintaining comparable efficacy to high-dose protocols for both peanut and milk allergies.
For peanut allergy, the standard 300 mg maintenance dose represents the best efficacy–safety balance. For milk allergy, maintaining a low fixed dose (3 mL / 99 mg) after initial desensitization is as effective as escalation to medium doses (25 mL / 825 mg), with significantly fewer adverse effects.


